Eterna Therapeutics Correlations
ERNA Stock | USD 0.26 0.01 3.70% |
The current 90-days correlation between Eterna Therapeutics and Palisade Bio is 0.06 (i.e., Significant diversification). The correlation of Eterna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Eterna Therapeutics Correlation With Market
Significant diversification
The correlation between Eterna Therapeutics and DJI is 0.07 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Eterna Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Eterna |
Moving together with Eterna Stock
Moving against Eterna Stock
0.46 | PG | Procter Gamble | PairCorr |
0.35 | LUCD | Lucid Diagnostics | PairCorr |
0.38 | T | ATT Inc Earnings Call Today | PairCorr |
0.35 | JNJ | Johnson Johnson | PairCorr |
0.31 | IBM | International Business | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Eterna Stock performing well and Eterna Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Eterna Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
RCUS | 2.55 | (0.75) | 0.00 | (0.76) | 0.00 | 3.18 | 22.17 | |||
CGEM | 2.58 | (0.40) | 0.00 | (0.73) | 0.00 | 5.13 | 15.27 | |||
ANNX | 3.54 | (0.73) | 0.00 | (0.62) | 0.00 | 5.94 | 26.02 | |||
GPCR | 3.70 | (0.37) | 0.00 | (0.27) | 0.00 | 6.92 | 25.66 | |||
RLAY | 4.18 | (0.40) | 0.00 | (0.27) | 0.00 | 6.27 | 26.72 | |||
REVB | 5.58 | (0.68) | 0.00 | (1.73) | 0.00 | 11.78 | 66.25 | |||
ZURA | 4.61 | (0.40) | 0.00 | (0.23) | 0.00 | 9.79 | 29.06 | |||
PHIO | 11.03 | 2.00 | 0.17 | 0.42 | 9.59 | 9.40 | 336.29 | |||
ZVSA | 4.67 | (0.29) | 0.00 | (0.82) | 0.00 | 12.03 | 38.26 | |||
RNAZ | 10.83 | (1.19) | 0.00 | (0.35) | 0.00 | 45.13 | 94.32 |
Eterna Therapeutics Corporate Management
Andrew Jackson | Chief Officer | Profile | |
Robert MD | Chief Officer | Profile | |
Susan McClatchey | VP Quality | Profile | |
Sandra Gurrola | Principal Finance | Profile | |
Megan Yung | Chief Officer | Profile | |
Roger MD | Chief Officer | Profile |